- Protalix BioTherapeutics, Inc. (AMEX:PLX) received European Commission approval for Elfabrio®, enhancing its financial position with a $25 million milestone payment.
- The company reported an earnings per share (EPS) of -$0.07, missing estimates, with revenues significantly lower than expected at $9.1 million.
- Despite financial setbacks, Protalix projects total revenues for 2026 to be between $78 million and $83 million, supported by strategic initiatives and a focus on expanding its pipeline through innovation and partnerships.
Protalix BioTherapeutics, Inc. (NYSE American: PLX) is a biopharmaceutical company focused on developing treatments for rare diseases. The company has made notable progress, particularly with the European Commission’s approval of the Elfabrio® dosing regimen for Fabry disease. This approval not only benefits patients but also resulted in a $25 million milestone payment from Chiesi, enhancing Protalix’s financial position.
On March 18, 2026, PLX reported an earnings per share (EPS) of -$0.07, missing the estimated EPS of $0.04. The company’s revenue was approximately $9.1 million, significantly lower than the expected $18.7 million. Despite these setbacks, Protalix anticipates a cash balance of around $50 million by April 2026, supported by strategic initiatives and milestone payments.
Protalix’s management projects total revenues for 2026 to be between $78 million and $83 million, including the milestone payment. The company is actively enrolling participants in a Phase 2 clinical trial for PRX-115, a potential therapy for uncontrolled gout. This focus on rare renal diseases aims to expand Protalix’s pipeline through innovation and partnerships.
Financially, PLX has a negative price-to-earnings (P/E) ratio of approximately -26.46, indicating current unprofitability. The price-to-sales ratio is about 3.39, suggesting investors pay $3.39 for every dollar of sales. The enterprise value to sales ratio is 3.27, showing a similar valuation when considering debt and cash.
The company’s debt-to-equity ratio is low at 0.17, indicating conservative debt use. The current ratio is 2.51, suggesting good short-term financial health with more than twice the current assets compared to liabilities. Despite challenges, Protalix remains focused on strategic advancements and clinical progress.
